Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification

被引:72
作者
Mian, Caterina [1 ]
Pennelli, Gianmaria [2 ]
Barollo, Susi [3 ]
Cavedon, Elisabetta [1 ]
Nacamulli, Davide [1 ]
Vianello, Federica [3 ]
Negro, Isabella [1 ]
Pozza, Giulia [2 ]
Boschin, Isabella Merante [4 ]
Pelizzo, Maria Rosa [4 ]
Rugge, Massimo [2 ]
Mantero, Franco [1 ]
Girelli, Maria Elisa [1 ]
Opocher, Giuseppe [3 ]
机构
[1] Dept Med & Surg Sci, Endocrinol Unit, Padua, Italy
[2] Dept Med Sci & Special Therapies, Pathol Unit, Padua, Italy
[3] Veneto Inst Oncol IRCCS, Padua, Italy
[4] Univ Padua, Dept Med & Surg Sci, Special Surg Unit, I-35128 Padua, Italy
关键词
TERM-FOLLOW-UP; SOMATIC MUTATIONS; CLINICOPATHOLOGICAL FEATURES; PROGNOSTIC-FACTORS; CALCITONIN; CANCER; PROTOONCOGENE;
D O I
10.1530/EJE-11-0079
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Medullary thyroid carcinoma (MTC) derives from the parafollicular C cells, being sporadic in 75% of cases and familial in 25%, due to RET proto-oncogene germinal mutations. In sporadic forms, stage at diagnosis is the most important negative prognostic factor. The aim of this study was to evaluate the prognostic impact of molecular and immunohistochemical markers in sporadic MTC. Design and methods: We studied 60 patients with sporadic MTC. For each case, we sought RET somatic mutations in the primary cancer and in lymph node metastases. The primary cancer also underwent immunohistochemical examination for Ki-67. Results: A somatic RET mutation was found in 38% of patients, being M918T in 52% of them. We observed a statistically significant association between RET mutations and male gender (P < 0.01), tumor size (P < 0.05), lymph nodes (P < 0.05) and distant metastases (P < 0.001), advanced stage (P < 0.05), increased risk of persistent disease (P=0.01), and low overall survival (P < 0.01). High Ki-67 levels were similarly associated with extra-thyroid spread (P < 0.05), lymph nodes (P < 0.05) and distant metastases (P < 0.001), advanced stage (P=0.01), and low overall survival (P=0.01). Combining somatic RET analysis with Ki-67 assessment seems to be useful for increasing the specificity of Ki-67 assessment alone and identifying patients with a more aggressive cancer: in our series, only the patients who died during the follow-up had both a somatic RET mutation and a Ki-67 expression level > 50 cells/mm(2). Conclusions: The combined evaluation of RET and Ki-67 could act as an adjuvant prognostic marker useful for ameliorating the initial risk stratification of patients with sporadic MTC.
引用
收藏
页码:971 / 976
页数:6
相关论文
共 23 条
  • [1] Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies
    Buergy, Daniel
    Weber, Theresia
    Maurer, Gabriele D.
    Mudduluru, Giridhar
    Medved, Fabian
    Leupold, Joerg H.
    Brauckhoff, Michael
    Post, Stefan
    Dralle, Henning
    Allgayer, Heike
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (04) : 894 - 901
  • [2] Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: Prognostic implications
    Cavalheiro, Beatriz G.
    Junqueira, Consuelo Rodrigues
    Brandao, Lenine G.
    [J]. THYROID, 2008, 18 (08) : 865 - 871
  • [3] DOTTORINI ME, 1999, CANCER, V77, P1556
  • [4] Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas
    Dvorakova, S.
    Vaclavikova, E.
    Sykorova, V.
    Vcelak, J.
    Novak, Z.
    Duskova, J.
    Ryska, A.
    Laco, J.
    Cap, J.
    Kodetova, D.
    Kodet, R.
    Krskova, L.
    Vlcek, P.
    Astl, J.
    Vesely, D.
    Bendlova, B.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 284 (1-2) : 21 - 27
  • [5] Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:: A 10-year follow-up study
    Elisei, Rossella
    Cosci, Barbara
    Romei, Cristina
    Bottici, Valeria
    Renzini, Giulia
    Molinaro, Eleonora
    Agate, Laura
    Vivaldi, Agnese
    Faviana, Pinuccia
    Basolo, Fulvio
    Miccoli, Paolo
    Berti, Piero
    Pacini, Furio
    Pinchera, Aldo
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (03) : 682 - 687
  • [6] Routine serum calcitonin measurement in the evaluation of thyroid nodules
    Elisei, Rossella
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (06) : 941 - 953
  • [7] Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer
    Faggiano, A.
    Grimaldi, F.
    Pezzullo, L.
    Chiofalo, M. G.
    Caraco, C.
    Mozzillo, N.
    Angeletti, G.
    Santeusanio, F.
    Lombardi, G.
    Colao, A.
    Avenia, N.
    Ferolla, P.
    [J]. ENDOCRINE-RELATED CANCER, 2009, 16 (01) : 225 - 231
  • [8] RET genotypes in sporadic medullary thyroid cancer:: studies in a large Italian series
    Fugazzola, Laura
    Muzza, Marina
    Mian, Caterina
    Cordella, Daniela
    Barollo, Susi
    Alberti, Luisella
    Cirello, Valentina
    Dazzi, Davide
    Girelli, Maria Elisa
    Opocher, Giuseppe
    Beck-Peccoz, Paolo
    Persani, Luca
    [J]. CLINICAL ENDOCRINOLOGY, 2008, 69 (03) : 418 - 425
  • [9] MEDULLARY-THYROID CARCINOMA - CLINICOPATHOLOGICAL FEATURES AND LONG-TERM FOLLOW-UP OF 65 PATIENTS TREATED DURING 1946 THROUGH 1970
    GHARIB, H
    MCCONAHEY, WM
    TIEGS, RD
    BERGSTRALH, EJ
    GOELLNER, JR
    GRANT, CS
    VANHEERDEN, JA
    SIZEMORE, GW
    HAY, ID
    [J]. MAYO CLINIC PROCEEDINGS, 1992, 67 (10) : 934 - 940
  • [10] Progression of medullary thyroid carcinoma:: assessment with calcitonin and carcinoembryonic antigen doubling times
    Giraudet, Anne Laure
    Al Ghulzan, Abir
    Auperin, Anne
    Leboulleux, Sophie
    Chehboun, Ahmed
    Troalen, Frederic
    Dromain, Clarisse
    Lumbroso, Jean
    Baudin, Eric
    Schlumberger, Martin
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (02) : 239 - 246